P5 Health Ventures
VC Fund
Fairfield, United States
P5 Health Ventures is a VC fund in Fairfield focused on Health Care and Medical. P5 Health Ventures invests in early stage companies that translate research and technology into platforms.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 10%
Last updated:
For AI agents: llms.txt
Industries P5 Health Ventures invests in
Health CareMedicalmHealthSoftwareBiotechnology
Stages P5 Health Ventures invests in
Series ASeedSeries B
Countries P5 Health Ventures invests in
United States
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
David Eigen
|
|||
Investment Focus
Industry
- Health Care 8 (80%)
- Medical 3 (30%)
- mHealth 3 (30%)
- Software 3 (30%)
- Biotechnology 2 (20%)
Stage
- Series A 5 (50%)
- Seed 2 (20%)
- Series B 2 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
David Eigen
Co-Founder and Managing Director
|
Co-Founder and Managing Director | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Genialis
|
Genialis is a precision medicine data science company focused on new ways to treat disease. Blending computational biology and AI-based methods, Genialis merges and models data at the intersection of clinical and translational medicine and drug discovery. Genialis is trusted by biopharma and big pharma alike, to validate targets, predict biomarkersand optimally position novel drugs. Together, Genialis and its partners are bringing improved solutions to drug discovery to change people's lives. | $13M / Series A / Mar 29, 2023 | |
Clarapath
|
Clarapath is a medical robotics company automating the laboratory. The company's first product is focused on fully automating the microtomy station in pathology. Their vision is to innovate, standardize, and digitally transform anatomic pathology through higher-quality lab medicine, more robust safety standards, and increased lab throughputwhile lowering laboratory costs and labor-related delays.Their next-generation laboratory at the NY Genome Center together with our large-scale image repository and analysis platform are designed to handle the entire “tissue to bits” pipeline for special research projects as well as larger-scale clinical needs. Clarapath works closely with both research and clinical customers to produce faster, more accurate results. | $16M / Series B / Nov 17, 2021 | |
FIGUR8
|
FIGUR8 is an MIT spin-off company, creating the most advanced wearable musculoskeletal (MSK) technology on the market. The solution combines Smart Biosensors, Intuitive Software and AI to analyze and advance musculoskeletal health. Our solution accurately pinpoints the source of MSK pathology and provides essential data to enhance patient-centricrecovery. Value is recorded across the entire episode of care, from injury through full recovery. FIGUR8 technology aids in significantly reducing the cost of care, improving access, and empowering patients to take control of their personal MSK health. | $12M / Series A / Jun 23, 2021 | |
Hawthorne Effect
|
Hawthorne Effect's mission is to make clinical trials accessible to everyone, everywhere. The company's proactive Visit Management System honors the relationship between sponsors and their investigators and promotes the use of shared technology to ensure protocol compliance and eliminate missing data. By enabling research teams to notonly track all of their patients and thousands of data points but deploy specially trained healthcare providers (“HEROs”) to conduct visits anywhere, anytime, Hawthorne Effect ensures that no patients are “lost to follow-up. | $20M / Series A / Jun 09, 2021 | |
Conversa Health
|
Conversa enables health systems to virtually engage, monitor and manage patients for chronic care, acute discharge, perioperative, oncology, OBGYN, prevention and wellness, and more. The automated care platform engages patients at high frequency and scale, while triaging to care venues when necessary, optimizing and improving the use of telehealthe-visits, phone calls and in-person consults. Conversa’s suite of COVID-19 Virtual Care Programs is being used by innovative organizations like UCSF Health, Northwell, UNC Health, Prisma Health and University Hospitals to provide symptom checking and triage, provide check-ins with quarantined patients, deliver lab results and screen employees, patients and visitors. | $8M / Series B / Jan 19, 2021 | |
|
Conversa Health
|
Conversa enables health systems to virtually engage, monitor and manage patients for chronic care, acute discharge, perioperative, oncology, OBGYN, prevention and wellness, and more. The automated care platform engages patients at high frequency and scale, while triaging to care venues when necessary, optimizing and improving the use of telehealthe-visits, phone calls and in-person consults. Conversa’s suite of COVID-19 Virtual Care Programs is being used by innovative organizations like UCSF Health, Northwell, UNC Health, Prisma Health and University Hospitals to provide symptom checking and triage, provide check-ins with quarantined patients, deliver lab results and screen employees, patients and visitors. | $12M / Series B / Jun 11, 2020 | |
|
FIGUR8
|
FIGUR8 is an MIT spin-off company, creating the most advanced wearable musculoskeletal (MSK) technology on the market. The solution combines Smart Biosensors, Intuitive Software and AI to analyze and advance musculoskeletal health. Our solution accurately pinpoints the source of MSK pathology and provides essential data to enhance patient-centricrecovery. Value is recorded across the entire episode of care, from injury through full recovery. FIGUR8 technology aids in significantly reducing the cost of care, improving access, and empowering patients to take control of their personal MSK health. | $4.5M / Seed / Aug 27, 2019 | |
Iterative Scopes
|
Iterative Scopes delivers tools for physicians and life sciences in colorectal cancer and inflammatory bowel disease space. The company was founded in 2017 and is based in Cambridge, Massachusetts. | $5.2M / Seed / Jun 15, 2019 | |
Babyscripts
|
Babyscripts’ three-tiered approach to virtual maternity care allows providers to deliver risk-specific care to pregnant mothers at any time, in any place. The first tier consists of a digital education layer delivered via a mobile app, with daily gestational-age and practice-specific, customizable content extending through one year postpartum toengage and empower pregnant mothers through trusted resources. The second tier enables virtual management of pregnant patients through the addition of remote monitoring. Depending on the risk, patients are provided with medical devices (like a bluetooth-enabled blood pressure cuff) to monitor for elevated risk, alerting the provider through a unique trigger alert system to enable risk management and intervention. This smart end-to-end management of patients enables the provider to transition care outside of the clinic and address problems of access, allowing them to automate a majority of their patient care while more effectively allocating time and resources to higher-risk patients. The third tier brings the insurer into the equation in a unique collaboration between the care team and payer, solving some of the structural issues of care coordination and access to care, improving outcomes while reducing cost. | $7.7M / Series A / Jul 20, 2017 | |
Cohero Health
|
Cohero Health offers a proprietary connected health platform for those with respiratory illness. Its sensor-based technology and engaging platform improve medication adherence and care coordination between patients and their care providers.The company offers a suite of tools and technology comprises form flexible inhaler sensors, mobilespirometers, to track real-time adherence and lung function, and a mobile application accessible on iPhone, iWatch, and Android. Cohero Health was founded in 2013 and is headquartered in New York. | $13.3M / Series A / Nov 02, 2016 |
Co-Investors
Northwell Ventures
6 deals together
Builders VC
4 deals together
Alumni Ventures
2 deals together
Debiopharm Innovation Fund
2 deals together
Genesis Merchant Capital
2 deals together
J-Ventures
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
SaaS Investors
99,274 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
SaaS VC Funds
61,208 investors
Software VC Funds
31,919 investors
Health Care VC Funds
32,370 investors
FAQ
What does P5 Health Ventures invest in?
P5 Health Ventures invests primarily in Health Care, Medical and mHealth startups, most often at Series A and Seed stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact P5 Health Ventures?
Public channels for P5 Health Ventures include X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at P5 Health Ventures?
The team at P5 Health Ventures includes David Eigen (Co-Founder and Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
